Clinical trials open for the enrollment
Title: 20200469 – A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer“
This trial investigates, in association to standard chemoimmunotherapic treatment (carboplatin-etoposide-atezolizumab/durvalumab), role of bispecific antibody tarlatamab, direct against DLL3 on tumor cells and CD3 on T lymphocytes
Principal Investigator: Prof. Pierfrancesco Tassone
Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Title: MILES-5: A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC
This study evaluates whether chemotherapy followed by immunotherapy (durvalumab) at progression or, conversely, immunotherapy (durvalumab, alone or in combination with tremelimumab) followed by chemotherapy at progression is more effective in patients aged 70 and over.
Principal Investigator: Prof. Pierfrancesco Tassone
For enrollment information please contact: Dr. Luigia Gervasi (Tel: +39 0961-3647921) Email: luigiagervasi@gmail.com
Title: DeLLphi-304 – “Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung cancer
Phase 3 study that investigates benefit in overall survival of tarlatamab respect to standard of care in small cell lung cancer relapsed after platinum-based treatment.
For enrollment information please contact: Dr. Luigia Gervasi (Tel: +39 0961-3647921) Email: luigiagervasi@gmail.com
Title: innovaTV207 – “Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors”
In this trial are investigated efficacy and safety of tisotumab vedotin, antbody- drugconjugate direct against tissutal factor, alone or in association with other drugs, in following neoplasms: colorectal, non-small cell lung cancer, exocrine pancrea, head and neck.
Principal Investigator: Prof. Pierfrancesco Tassone
For enrollment information please contact: Dr. Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Title: CA043-001 – An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Phase 1/2 first-in-human trial that investigates role of BMS-986288 (a modified form of ipilimumab), alone or in association to nivolumab, in various tumors.
Principal Investigator: Prof. Pierfrancesco Tassone
ENROLLMENT ACTUALLY NOT ACTIVE
Clinical trials closed for the enrollment
Title: ROME – “The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: CA209-73L – “A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: EVOKE-01 – “Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: CANOPY-2 – “A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: D4194R00005 – “First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: MK7902-007 – “A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: MS200647_0037 – “An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: BE-PACIFIC – “Italian oBsErvational study on Patient mAnagement strategies in real-world Clinical practIce For patIents with loCally advanced (stage III) NSCLC”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: MO39171 – “A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: OSIRIS – “(OSImertinib Rechallenge TKI in Subsequent line of therapy) A Phase II, Noncomparative, Open label. Multicentre, Study of AZD9291, in Patients with Locally Advanced or Metastatic EGFR mutated, “T760M undetectable or unknown” Non Small Cell Lung Cancer (Stage IIIB-IV) after No immediate Prior EGFR TKI”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: CINC280A2201 – “A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: PIvOTAL – “Global treatment Patterns, resource utilization and bIOmarker Testing of Advanced non-small cell Lung cancer”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: Vx-001-201 – “Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: Be-Team – “Italian observational study on second-line treatment approaches for EGFR mutated, progressing NSCLC patients in real world clinical practice”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: BEVERLY – “A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: INSIGHT – “A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (EMR 200095-006)”
Principal Investigator: Prof. Pierfrancesco Tassone
Title: PROFILE 1014 – “Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: CLDK378A2301 – “A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: TORCH – “An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: MO19390 – “Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: STAD-1 – “Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: MILES-3 – “Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer”
Principal Investigator: Prof. Pierosandro Tagliaferri
Title: MILES-4 – “A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC”
Principal Investigator: Prof. Pierosandro Tagliaferri